

LISTA LUCRARI PUBLICATE ADRIAN PAVEL TRIFA

ARTICOLE PUBLICATE IN EXTENSO IN REVISTE ISI

1. Cruceriu D, Baldasici O, Balacescu L, Gligor-Popa S, Flonta M, Man MA, Visan S, Vlad C, **Trifa AP**, Balacescu O, Achimas-Cadariu P. Critical Aspects Concerning the Development of a Pooling Approach for SARS-CoV-2 Diagnosis Using Large-Scale PCR Testing. *Viruses*. 2021; 13(5):902. <https://doi.org/10.3390/v13050902>. **ISI, FI = 3.816**
2. Suciu-Petrescu M, Truta A, Suciu MD, **Trifa AP**, Petrescu D, Roşianu HŞ, Sabin O, Popa DE, Macarie AE, Vesa ŞC, Buzoianu AD. Clinical impact of echocardiography parameters and molecular biomarkers in heart failure: Correlation of ACE2 and MCP-1 polymorphisms with echocardiography parameters: A comparative study. *Exp Ther Med*. 2021 Jul;22(1):686. doi: 10.3892/etm.2021.10118. Epub 2021 Apr 28. **ISI, FI = 1.785**
3. Iluta S, Pasca S, Dima D, Mester G, Urian L, Bojan A, Zdrenghia M, **Trifa A**, Balacescu O, Tomuleasa C. Haematology patients infected with SARS-CoV-2, pretreated with eculizumab or siltuximab, develop oligosymptomatic disease. *Eur J Hosp Pharm*. 2021 Feb 4;ejhpharm-2021-002694. doi: 10.1136/ejhpharm-2021-002694. Online ahead of print. **ISI, FI = 0.892**
4. Mirea AM, Pop RM, Căinap SS, **Trifa AP**. Presymptomatic diagnosis of CYP24A1-related infantile idiopathic hypercalcemia: A case report. *Eur J Med Genet*. 2020 Dec;63(12):104100. doi: 10.1016/j.ejmg.2020.104100. Epub 2020 Nov 10. **ISI, FI = 2.022**
5. Lighezan DL, Bojan AS, Iancu M, Pop RM, Gligor-Popa Ş, Tripon F, Cosma AS, Tomuleasa C, Dima D, Zdrenghia M, Fetica B, Ioniţă I, Gaál IO, Vişan S, Mirea AM, Popp RA, Florea M, Araniciu C, Petrescu L, Pop IV, Bănescu C, **Trifa AP**. TET2 rs1548483 SNP Associating with Susceptibility to Molecularly Annotated Polycythemia Vera and Primary Myelofibrosis. *J Pers Med*. 2020 Dec 1;10(4):259. doi: 10.3390/jpm10040259. **ISI, FI = 4.433**
6. Roşian AN, Iancu M, **Trifa AP**, Roşian ŞH, Mada C, Gocan CP, Niţă T, Istratoaie S, Boarescu PM, Buzoianu AD. An Exploratory Association Analysis of ABCB1 rs1045642 and ABCB1 rs4148738 with Non-Major Bleeding Risk in Atrial Fibrillation Patients Treated with Dabigatran or Apixaban. *J Pers Med*. 2020 Sep 18;10(3):E133. doi: 10.3390/jpm10030133. **ISI, FI = 3.59**
7. Toma C, Bâlţeanu VA, Tripon S, **Trifa A**, Rema A, Amorim I, Pop RM, Popa R, Catoi C, Taulescu M. Exogenous Jaagsiekte Sheep Retrovirus type 2 (exJSRV2) related to ovine pulmonary adenocarcinoma (OPA) in Romania: prevalence, anatomical forms, pathological description, immunophenotyping and virus identification. *BMC Vet Res*. 2020 Aug 17;16(1):296. doi: 10.1186/s12917-020-02521-1. **ISI, FI = 1.792**
8. Turcas C, Moisoiu V, Stefanu A, Jurj A, Iancu SD, Teodorescu P, Pasca S, Bojan A, **Trifa A**, Iluta S, Zimta AA, Petrushev B, Zdrenghia M, Bumbea H, Coriu D, Dima D, Leopold N, Tomuleasa C. SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia? *Front Oncol*. 2020 Jun 29;10:1024. doi: 10.3389/fonc.2020.01024. eCollection 2020. **ISI, FI = 4.416**.

9. Vesa SC, Vlaicu SI, Vacaras V, Crisan S, Sabin O, Pasca S, **Trifa AP**, Rusz-Fogarasi T, Sava M, Buzoianu AD. CYP4F2 and VKORC1 Polymorphisms Amplify the Risk of Carotid Plaque Formation. *Genes (Basel)*. 2020 Jul 20;11(7):822. doi: 10.3390/genes11070822. **ISI. FI = 3.759.**
10. Pop RM, **Trifa AP**, Popolo A, Chedea VS, Militaru C, Bocsan IC, Buzoianu AD. *Nigella sativa*: Valuable perspective in the management of chronic diseases. *Iran J Basic Med Sci*. 2020 Jun;23(6):699-713. doi: 10.22038/ijbms.2020.37734.8978. **ISI. FI = 1.96.**
11. Tripon F, Iancu M, **Trifa A**, Crauciuc GA, Boglis A, Balla B, Cosma A, Dima D, Candea M, Lazar E, Jimbu L, Banescu C. Association Analysis of TP53 rs1042522, MDM2 rs2279744, rs3730485, MDM4 rs4245739 Variants and Acute Myeloid Leukemia Susceptibility, Risk Stratification Scores, and Clinical Features: An Exploratory Study. *J Clin Med*. 2020 Jun 1;9(6):1672. doi: 10.3390/jcm9061672. **ISI. FI = 3.303**
12. Roşian AN, Roşian ŞH, Kiss B, Ştefan MG, **Trifa AP**, Ober CD, Anchidin O, Buzoianu AD. Interindividual Variability of Apixaban Plasma Concentrations: Influence of Clinical and Genetic Factors in a Real-Life Cohort of Atrial Fibrillation Patients. *Genes (Basel)*. 2020 Apr 17;11(4):438. doi: 10.3390/genes11040438. **ISI. FI = 3.759.**
13. Tripon F, Crauciuc GA, Bogliş A, Moldovan V, Sándor-Kéri J, Benedek IJ, **Trifa AP**, Bănescu C. Co-occurrence of PML-RARA gene fusion, chromosome 8 trisomy, and FLT3 ITD mutation in a young female patient with de novo acute myeloid leukemia and early death: A CARE case report. *Medicine (Baltimore)*. 2020 Apr;99(14):e19730. doi: 10.1097/MD.00000000000019730. **ISI. FI = 1.552**
14. Tripon F, Iancu M, **Trifa A**, Crauciuc GA, Boglis A, Dima D, Lazar E, Bănescu C. Modelling the Effects of MCM7 Variants, Somatic Mutations, and Clinical Features on Acute Myeloid Leukemia Susceptibility and Prognosis. *J Clin Med*. 2020 Jan 8;9(1):158. doi: 10.3390/jcm9010158. **ISI. FI = 3.303.**
15. **Trifa AP**, Lighezan DL, Jucan C, Tripon F, Arbore DR, Bojan A, Gligor-Popa S, Pop RM, Dima D, Bănescu C. SH2B3 (LNK) rs3184504 polymorphism is correlated with JAK2 V617F-positive myeloproliferative neoplasms. *Rev Romana Med Lab*. 2020;28(3):267-77. DOI:10.2478/rmlm-2020-0025. **ISI. FI = 0.945**
16. Dobrowolski J, Pasca S, Teodorescu P, Selicean C, Rus I, Zdrenghia M, Bojan A, **Trifa A**, Fetica B, Petrushev B, Rosu AM, Berindan-Neagoe I, Tomuleasa C, Dima D. Persistent Basophilia May Suggest an “Accelerated Phase” in the Evolution of CALR-Positive Primary Myelofibrosis Toward Acute Myeloid Leukemia. *Front. Oncol.*, 06 September 2019 | <https://doi.org/10.3389/fonc.2019.00872>. [Epub ahead of print]. **ISI. FI = 4.416.**
17. Vesa ŞC, Chira R, Vlaicu SI, Paşca S, Crişan S, **Trifa A**, Buzoianu AD. Systemic and Local Factors' Influence on the Topological Differences in Deep Vein Thrombosis. *Medicina (Kaunas)*. 2019 Oct 16;55(10):691. doi: 10.3390/medicina55100691. **ISI. FI = 1.5.**
18. Ciubean AD, Ungur RA, Irsay L, Ciortea VM, Borda IM, Dogaru GB, **Trifa AP**, Vesa SC, Buzoianu AD. Polymorphisms of FDPS, LRP5, SOST and VKORC1 genes and their relation with osteoporosis in postmenopausal Romanian women.

- PLoS One. 2019 Nov 27;14(11):e0225776. doi: 10.1371/journal.pone.0225776. eCollection 2019. **ISI. FI = 2.74**
19. Bănescu C, Tripon F, **Trifa AP**, Crauciuc AG, Bogliș A, Lazar E, Dima D, Macarie I, Duicu C, Iancu M. Presence of copy number aberration and clinical prognostic factors in patients with acute myeloid leukemia: an analysis of effect modification. *Pol Arch Intern Med.* 2019 Dec 23;129(12):898-906. doi: 10.20452/pamw.15093. **ISI. IF = 3.007**
 20. Bănescu C, Tripon F, **Trifa AP**, Crauciuc AG, Moldovan VG, Bogliș A, Benedek I, Dima D, Căndea M, Duicu C, Iancu M. Cytokine rs361525, rs1800750, rs1800629, rs1800896, rs1800872, rs1800795, rs1800470, and rs2430561 SNPs in relation with prognostic factors in acute myeloid leukemia. *Cancer Med.* 2019 Aug 1. doi: 10.1002/cam4.2424. [Epub ahead of print]. **ISI; FI = 1.425.**
 21. Vasilovici AF, Grigore LE, Ungureanu L, Fehete O, Candrea E, **Trifa AP**, Vișan S, Șenilă S, Cosgarea R. Vitamin D receptor polymorphisms and melanoma. *Oncol Lett.* 2019 May;17(5):4162-4169. **ISI; FI = 1.664.**
 22. **Trifa AP**, Bănescu C, Voina CM, Popa Ș, Török-Vistai T, Bojan AS, Dima D, Zdrenghea M, Fetica B, Vișan S, Tomuleasa C, Pârvu A, Urian L, Pop B, Popov VM, Andreescu M, Popp RA. Modest contribution of JAK2 V617F allele burden to the occurrence of major thrombosis in polychthemia vera and essential thrombocythemia. *Blood Cells Mol Dis.* 2018 Nov;73:45-46. doi: 10.1016/j.bcmd.2018.09.003. **ISI; FI = 1.836.**
 23. Jurj A, Pop L, Petrushev B, Pasca S, Dima D, Frinc I, Deak D, Desmirean M, **Trifa A**, Fetica B, Gafencu G, Selicean S, Moisoiu V, Micu WT, Berce C, Sacu A, Moldovan A, Colita A, Bumbea H, Tanase A, Dascalescu A, Zdrenghea M, Stiuțiu R, Leopold N, Tetean R, Burzo E, Tomuleasa C, Berindan-Neagoe I. Exosome-carried microRNA-based signature as a cellular trigger for the evolution of chronic lymphocytic leukemia into Richter syndrome. *Crit Rev Clin Lab Sci.* 2018 Nov;55(7):501-515. **ISI; FI = 6.481**
 24. Pop RM, Popolo A, **Trifa AP**, Stanciu LA. Phytochemicals in Cardiovascular and Respiratory Diseases: Evidence in Oxidative Stress and Inflammation. *Oxid Med Cell Longev.* 2018 Aug 9;2018:1603872. doi: 10.1155/2018/1603872. **ISI; FI = 4.936**
 25. Dima D, Oprita L, Rosu AM, **Trifa A**, Selicean C, Moisoiu V, Frinc I, Zdrenghea M, Tomuleasa C. Adult acute megakaryoblastic leukemia: rare association with cytopenias of undetermined significance and p210 and p190 BCR-ABL transcripts. *Onco Targets Ther.* 2017 Oct 19;10:5047-5051. doi: 10.2147/OTT.S146973. **ISI; FI = 2.656**
 26. **Trifa AP**, Bănescu C, Bojan AS, Voina CM, Popa Ș, Vișan S, Ciubean AD, Tripon F, Dima D, Popov VM, Vesa ȘC, Andreescu M, Török-Vistai T, Mihăilă RG, Berbec N, Macarie I, Coliță A, Iordache M, Cătană AC, Farcaș MF, Tomuleasa C, Vasile K, Truică C, Todincă A, Pop-Muntean L, Manolache R, Bumbea H, Vlădăreanu AM, Gaman M, Ciufu CM, Popp RA. MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients. *Am J Hematol.* 2018 Jan;93(1):100-106. doi: 10.1002/ajh.24946. **ISI; FI = 6.137**
 27. Tomuleasa C, Zaharie F, Muresan MS, Pop L, Fekete Z, Dima D, Frinc I, **Trifa A**, Berce C, Jurj A, Berindan-Neagoe I, Zdrenghea M. How to Diagnose and Treat

- a Cancer of Unknown Primary Site. *J Gastrointestin Liver Dis.* 2017 Mar;26(1):69-79. doi: 10.15403/jgld.2014.1121.261.haz. **ISI; FI = 1.964**
28. Groza I, Matei D, Tantau M, **Trifa AP**, Crisan S, Vesa SC, Bocsan C, Buzoianu AD, Acalovschi M. VKORC1-1639 G>A Polymorphism and the Risk of Non-Variceal Upper Gastrointestinal Bleeding. *J Gastrointestin Liver Dis.* 2017 Mar;26(1):13-18. doi: 10.15403/jgld.2014.1121.261.vko. **ISI; FI = 1.964**
29. Tomuleasa C, Selicean S, Gafencu G, Petrushev B, Pop L, Berce C, Jurj A, **Trifa A**, Rosu AM, Pasca S, Magdo L, Zdrenghea M, Dima D, Tanase A, Frinc I, Bojan A, Berindan-Neagoe I, Ghiaur G, Ciurea SO. Fibroblast dynamics as an in vitro screening platform for anti-fibrotic drugs in primary myelofibrosis. *J Cell Physiol.* 2018 Jan;233(1):422-433. doi: 10.1002/jcp.25902. **ISI; FI = 3.923**
30. **Trifa AP**, Bănescu C, Dima D, Bojan AS, Tevet M, Moldovan VG, Vesa ŞC, Murat M, Pop IV, Skrypnyk C, Popp RA. Among a panel of polymorphisms in genes related to oxidative stress, CAT-262 C>T, GPX1 Pro198Leu and GSTP1 Ile105Val influence the risk of developing BCR-ABL negative myeloproliferative neoplasms. *Hematology.* 2016 Oct;21(9):520-5. doi: 10.1080/10245332.2016.1163889. **ISI; FI = 1.315**
31. **Trifa AP**, Bănescu C, Tevet M, Bojan A, Dima D, Urian L, Török-Vistai T, Popov VM, Zdrenghea M, Petrov L, Vasilache A, Murat M, Georgescu D, Popescu M, Pătrinoiu O, Balea M, Costache R, Coleş E, Şaguna C, Berbec N, Vlădăreanu AM, Mihăilă RG, Bumbea H, Cucuianu A, Popp RA. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients. *Br J Haematol.* 2016 Jul;174(2):218-26. doi: 10.1111/bjh.14041. **ISI; FI = 5.67**
32. Petrisor FM, Catana A, Marginean DH, **Trifa AP**, Popp RA, Pop IV. FGB -455 G>A and GP IIIa PIA1/A2 polymorphisms in a group of Romanian stroke patients. *Rom Rev Lab Med.*2016;24:45-54; **ISI; FI = 0.325**
33. Daraban AM, **Trifa AP**, Popp RA, Botezatu D, Serban M, Uscatescu V, Talmaci R, Coriu D, Ginghina C, Jurcut RO. Thrombophilia genetic testing in Romanian young women with acute thrombotic events: role of Factor V Leiden, Prothrombin G20210A, MTHFR C677T and A1298C polymorphisms. *Rom Rev Lab Med.*2016; 24(3):291-305. DOI:10.1515/rrlm-2016-0032. **ISI; FI = 0.325**
34. Bănescu C, Iancu M, **Trifa AP**, Căndea M, Benedek Lazar E, Moldovan VG, Duicu C, Tripon F, Crauciuc A, Dobreanu M. From Six Gene Polymorphisms of the Antioxidant System, Only GPX Pro198Leu and GSTP1 Ile105Val Modulate the Risk of Acute Myeloid Leukemia. *Oxid Med Cell Longev.* 2016;2016:2536705. doi: 10.1155/2016/2536705. **ISI; FI = 4.593**
35. Bănescu C, Iancu M, **Trifa AP**, Dobreanu M, Moldovan VG, Duicu C, Tripon F, Crauciuc A, Skypnyk C, Bogliş A, Lazar E. Influence of XPC, XPD, XPF, and XPG gene polymorphisms on the risk and the outcome of acute myeloid leukemia in a Romanian population. *Tumour Biol.* 2016 Jul;37(7):9357-66. doi: 10.1007/s13277-016-4815-6. **ISI; FI = 3.65**
36. Vesa ŞC, **Trifa AP**, Crişan S, Buzoianu AD. VKORC1 -1639 G>A Polymorphism in Romanian Patients With Deep Vein Thrombosis. *Clin Appl Thromb Hemost.* 2016 Nov;22(8):760-764. **ISI; FI = 2.096**
37. Costache RM, Bănescu C, Popp RA, Pop IV, **Trifa AP**. The glucocorticoid receptor A3669G SNP is not associated with polycythemia vera, essential

- thrombocytopenia or primary myelofibrosis. *Leuk Lymphoma*. 2016;57(1):209-11. doi: 10.3109/10428194.2015.1046065. **ISI; FI = 2.755**
38. Bănescu C, Iancu M, **Trifa AP**, Macarie I, Dima D, Dobreanu M. The methylenetetrahydrofolate reductase (MTHFR) 677 C>T polymorphism increases the risk of developing chronic myeloid leukemia-a case-control study. *Tumour Biol*. 2015 Apr;36(4):3101-7. doi: 10.1007/s13277-014-2946-1. **ISI; FI = 2.926**
39. Bănescu C, **Trifa AP**, Voidăzan S, Moldovan VG, Macarie I, Benedek Lazar E, Dima D, Duicu C, Dobreanu M. CAT, GPX1, MnSOD, GSTM1, GSTT1, and GSTP1 genetic polymorphisms in chronic myeloid leukemia: a case-control study. *Oxid Med Cell Longev*. 2014;2014:875861. doi: 10.1155/2014/875861. **ISI; FI = 3.516**
40. **Trifa AP**, Cucuianu A, Popp RA, Pațiu M, Selicean C, Militaru MS, Pop IV. Concomitant Myeloproliferative and Lymphoid Neoplasms in Two Patients Positive for JAK2 V617F Mutation. Case Report and Literature Review. *Indian J Hematol Blood Transfus*. 2014 Sep;30(Suppl 1):120-3. doi: 10.1007/s12288-013-0281-0. **ISI; FI = 0.234**
41. Cucuianu A, Pațiu M, **Trifa AP**, Tomuleasa C, Dima D. Redistribution of iron towards deposits in erythroblastopenic anemia as a consequence of decreased erythroferrone production. *Med Hypotheses*. 2014 Nov;83(5):530-2. doi: 10.1016/j.mehy.2014.09.008. **ISI; FI = 1.074**
42. Bănescu C, **Trifa AP**. Methylenetetrahydrofolate reductase 677 C> T polymorphism is associated with acute myeloid leukemia. *Leuk Lymphoma*. 2015 Apr;56(4):1172-4. doi: 10.3109/10428194.2014.955024. **ISI; FI = 3.093**
43. Trifa AP, Popp RA, Cucuianu A, Bănescu C, Tevet M, Martin B, Murat M, Vesa SC, Dima D, Căndea M, Militaru MS, Pop IV. CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients. *Br J Haematol*. 2015 Jan;168(1):151-3. doi: 10.1111/bjh.13076. **ISI; FI = 5.812**
44. Bănescu C, **Trifa AP**, Demian S, Benedek Lazar E, Dima D, Duicu C, Dobreanu M. Polymorphism of XRCC1, XRCC3, and XPD genes and risk of chronic myeloid leukemia. *Biomed Res Int*. 2014;2014:213790. doi: 10.1155/2014/213790. **ISI; FI = 2.706**
45. Pop TR, Vesa ȘC, **Trifa AP**, Crișan S, Buzoianu AD. PAI-1 4G/5G and MTHFR C677T polymorphisms increased the accuracy of two prediction scores for the risk of acute lower extremity deep vein thrombosis. *Rom J Morphol Embryol*. 2014;55(1):153-7. **ISI; FI = 0.723**
46. **Trifa AP**, Cucuianu A, Popp RA, Coadă CA, Costache RM, Militaru MS, Vesa SC, Pop IV. The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocytopenia. *Ann Hematol*. 2014;93(2):203-209. **ISI; FI = 2.866**
47. Pop TR, Vesa Ș, **Trifa AP**, Crișan S, Buzoianu AD. An acenocoumarol dose algorithm based on a South-Eastern European population. *Eur J Clin Pharmacol*. 2013 Nov;69(11):1901-7. doi: 10.1007/s00228-013-1551-3. **ISI; FI = 2.741**
48. Bănescu C, Duicu C, **Trifa AP**, Dobreanu M. XRCC1 Arg194Trp and Arg399Gln polymorphisms are significantly associated with shorter survival in acute

- myeloid leukemia. Leuk Lymphoma. 2013.doi:10.3109/10428194.2013.802781. **ISI; FI = 2.301**
49. Militaru FC, Vesa SC, Crisan S, Militaru V, **Trifa AP**, Buzoianu AD. Genotype-phenotype correlations in patients treated with acenocoumarol. *Rom Rev Med Lab.* 2014;22(3):347-54. **ISI; FI = 0.171**
50. Hotoleanu C, **Trifa A**, Popp R, Fodor D. The importance of homozygous polymorphisms of methylenetetrahydrofolate reductase gene in romanian patients with idiopathic venous thromboembolism. *Balkan Med J.* 2013 Jun;30(2):197-203. **ISI; FI = 0.169**
51. Dima D, **Trifa AP**, Patiu M, Vesa SC, Frinc IC, Petrov L, Cucuianu A. Tyrosine kinase inhibitor treatment outcome in a single center cohort of chronic myeloid leukemia patients. The role of the T315I ABL kinase domain mutation. *Rom Rev Lab Med.* 2013;21(1):29-37. **ISI; FI = 0.171**
52. **Trifa AP**, Cucuianu A, Popp RA, Coada CA, Costache RM, Sarca AD, Farcas MF, Militaru MS, Pop IV. No association between the STAT5b rs6503691 (C>T) SNP and myeloproliferative neoplasms. *Eur J Haematol.* 2013;90(3):257-8. **ISI; FI = 2.548**
53. **Trifa AP**, Cucuianu A, Popp RA, Costache RM, Coada CA, Sarca AD, Urian LG, Dima D, Petrov L, Farcas MF, Militaru MS, Pop IV. Analysis of the MTHFR (methylenetetrahydrofolate reductase) 677 C>T and 1298 A>C polymorphisms in BCR-ABL-negative myeloproliferative neoplasms. *Int J Lab Hematol.* 2013; 35(1):e9-12. **ISI; FI = 1.293**
54. **Trifa AP**, Popp RA, Cucuianu A, Coada CA, Urian LG, Militaru MS, Banescu C, Dima D, Farcas MF, Crişan TO, Petrov L, Gug C, Pop IV. Absence of BRAF V600E mutation in a cohort of 402 patients with various chronic and acute myeloid neoplasms. *Leuk Lymphoma.* 2012;53(12):2496-7. **ISI; FI = 2.580**
55. Buzoianu AD, Militaru FC, Vesa SC, **Trifa AP**, Crişan S. The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population. *Blood Cells Mol Dis.* 2013 Mar;50(3):166-70. doi: 10.1016/j.bcmd.2012.10.010. **ISI; FI = 2.331**
56. Buzoianu AD, **Trifa AP**, Mureşanu DF, Crişan S. Analysis of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms in a population from South-Eastern Europe. *J Cell Mol Med.* 2012 Dec;16(12):2919-24. doi: 10.1111/j.1582-4934.2012.01606.x. **ISI; FI = 4.753**
57. **Trifa AP**, Popp RA, Militaru MS, Farcas MF, Crisan TO, Gana I, Cucuianu A, Pop IV. J Gastrointestin Liver Dis. HFE Gene C282Y, H63D and S65C mutations frequency in the Transylvania region, Romania. 2012;21(2):177-80. **ISI; FI = 1.811**
58. Urian L, **Trifa AP**, Petrov L, Patiu M. Clinical, laboratory and molecular features in essential thrombocythemia. *Rom Rev Lab Med.* 2011; 19(2):129-38. **ISI; FI = 0.091**
59. Kacso IM, **Trifa AP**, Popp RA, Kacso G. Association of 276G>T adiponectin gene polymorphism to plasma adiponectin and albuminuria in type 2 diabetic patients. *Int Urol Nephrol.* 2012 Dec;44(6):1771-7. doi: 10.1007/s11255-011-0118-4. **ISI; FI = 1.471**
60. Crişan TO, Farcaş MF, **Trifa AP**, Plantinga TS, Militaru MS, Pop IV, Netea MG, Popp RA. TLR1 polymorphisms in Europeans and spontaneous pregnancy loss. *Gene.* 2012 Feb 15;494(1):109-11. doi: 10.1016/j.gene.2011.12.008. **ISI; FI = 2.341**

61. Crișan TO, **Trifa A**, Farcaș M, Militaru M, Netea M, Pop I, Popp R. The MTHFD1 c.1958 G>A polymorphism and recurrent spontaneous abortions. *J Matern Fetal Neonatal Med.* 2011 Jan;24(1):189-92. doi: 10.3109/14767051003702794. **ISI; FI = 1.495**
62. Lazăr C, Popp R, **Trifa A**, Mocanu C, Mihut G, Al-Khzouz C, Tomescu E, Figan I, Grigorescu-Sido P. Prevalence of the c.35delG and p.W24X mutations in the GJB2 gene in patients with nonsyndromic hearing loss from North-West Romania. *Int J Pediatr Otorhinolaryngol.* 2010 Apr;74(4):351-5. doi: 10.1016/j.ijporl.2009.12.015. **ISI; FI = 1.167**
63. **Trifa AP**, Cucuianu A, Petrov L, Urian L, Militaru MS, Dima D, Pop IV, Popp RA. The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms. *Ann Hematol.* 2010;89(10):979-83. **ISI; FI = 2.615**
64. **Trifa AP**, Cucuianu A, Popp RA, Development of a reliable PCR-RFLP assay for investigation of the JAK2 rs10974944 SNP, which might predispose to the acquisition of somatic mutation JAK2(V617F). *Acta Haematol.* 2010;123(2):84-7. **ISI; FI = 1.354**
65. **Trifa AP**, Crisan S, Popp RA, Cucuianu A, Buzoianu AD. JAK2 46/1 haplotype seems not to be associated with lower limb deep venous thrombosis. *Blood Cells Mol Dis.* 2010 ;45(3):199-200. **ISI; FI = 2.351**
66. Buzoianu AD, **Trifa AP**, Popp RA, Militaru MS, Militaru CF, Bocsan CI, Farcaș MF, Pop IV. Screening for CYP2C19*2, *3 and *4 gene variants in a Romanian population study group. *Farmacologia.* 2010;58(6):806-17. **ISI; FI = 0.850**
67. Militaru MS, Popp RA, **Trifa AP**. Homozygous G320V mutation in the HJV gene causing juvenile hereditary haemochromatosis type A. A case report. *J Gastrointest Liver Dis.* 2010 Jun;19(2):191-3. **ISI; FI = 1.811**
68. Farcaș MF, **Trifa AP**, Militaru M, Csernik FA, Crisan TO, Popp RA. Association of methionine synthase A2756G SNP, methionine synthase reductase A66G and male infertility. *Rom Rev Med Lab.* 2010; 17(4):17-25. **ISI**
69. **Trifa AP**, Popp RA, Cucuianu A, Dima D, Militaru MS, Patiu M, Pop IV. JAK2 p.V617F mutation - tetra-primer PCR and PCR-RFLP comparative semiquantitative approaches for estimation of the mutant allele in myeloproliferative neoplasms. *Rom Rev Med Lab.* 2009; 14(1):25-30. **ISI**
70. Hotoleanu C, Popp R, **Trifa AP**, Nedelcu L, Dumitrascu DL. Genetic determination of irritable bowel syndrome. *World J Gastroenterol.* 2008 Nov 21;14(43):6636-40. doi: 10.3748/wjg.14.6636. **ISI, FI = 2.081**

ARTICOLE PUBLICATE IN EXTENSO IN REVISTE BDI

1. Michiels JJ, Tevet M, **Trifa A**, Niculescu-Mizil E, Lupu A, Vladareanu AM, Bumbea H, Ilea A, Dobrea C, Georgescu D, Patrinoiu O, Popescu M, Murat M, Dragan C, Mihai F, Zurac S, Angelescu S, Iova A, Popa A, Gogulescu R, Popov V. 2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and Therapeutic Implications. *Maedica (Buchar)*. 2016 Mar;11(1):5-25.
2. **Trifa AP**, Cucuianu A, Popp RA. Familial Essential Thrombocythemia Associated with MPL W515L Mutation in Father and JAK2 V617F Mutation in Daughter. *Case Rep Hematol*. 2014;2014:841787. doi: 10.1155/2014/841787.
3. **Trifa AP**, Patiu M, Cucuianu A, Dima D, Militaru MS, Pop IV, Popp RA. Systemic mastocytosis associated with the C-KIT D816V mutation – importance of molecular diagnosis and therapeutic implications. Case report. *Timisoara Medical Journal*.2010; 60(2-3):241-47.
4. Popp RA, Crisan TO, Rotar I, Farcas MF, **Trifa AP**, Militaru MS, Pop IV. Cystathionine β -synthase 844ins68 Genetic Polymorphism in Spontaneous Abortion Susceptibility. *Applied Medical Informatics* 2011; 29(4):34-40.
5. Sabin O, **Trifa AP**, Brusturean E, Buzoianu AD. Study of CYP2C9 and CYP2C19 polymorphisms in a Romanian epilepsy population. *HVM Bioflux*.2013; 5(3): 77-81.
6. Farcas MF, **Trifa AP**, Popp RA, Crisan TO, Militaru MS, Pop IV, Lazar C. Screening for 35delG and W24X in the GJB2 gene in a Romanian population group. *Annals of RSBC*.2010;XV(1):304-10.
7. **Trifa AP**, Popp RA, Militaru MS, Farcas MF, Crisan T, Petrisor F, Pop IV. Prevalence of Factor V Leiden and Prothrombin G20210A mutations among a group of women with recurrent spontaneous abortions. *Annals of RSCB*. 2009;XIV (2):42-46.
8. **Trifa AP**, Popp RA, Militaru MS, Crisan TO, Farcas MF, Csernik FA, Petrisor F, Pop IV, Buzoianu AD. The C and T alleles of the MDR1 C3435T polymorphism share similar frequencies in the Romanian population. *Annals of RSCB*. 2009;XIV(1):68-73.
9. Farcas MF, Csernik FA, Popp RA, **Trifa AP**, Crisan T, Petrisor F, Pop IV, Militaru M. The Interleukin 4 VNTR polymorphism frequency in a Romanian population group. *Annals of RSCB*. 2009; XIV(1):97-102.
10. Farcas MF, **Trifa AP**, Militaru M, Csernik FA, Crisan T, Pop IV, Popp RA. Methylenetetrahydrofolate reductase A1298C polymorphism and male infertility in a Romanian population group. *Maedica - A Journal of Clinical Medicine*. 2009;4(4):294-299.
11. Farcas MF, **Trifa AP**, Militaru M, Csernik FA, Crişan T, Pop IV, Popp RA. Methylenetetrahydrofolate reductase G1793A polymorphism and male infertility in a Romanian population group. *Studia Universitatis “Vasile Goldiş”, Seria Ştiinţele Vieţii* .2010; 20(1):31-5.
12. Popp RA, Badea M, Hedesiu M, **Trifa AP**, Serbanescu A, Farcas MF, Crisan TO, Tosa F, Petrisor F, Badea AF, Militaru MS. The -799C/T polymorphism of the

- matrixmetalloproteinase 8 (MMP8) gene in periodontal disease – a case-control study. *Annals of RSCB*. 2009;XIV(2):67-72.
13. Farcas MF, Antonesei M, **Trifa AP**, Popp RA, Crisan TO, Petrisor F, Pop IV. Molecular diagnosis of β -thalassaemia in a Romanian population group. *Annals of RSCB*. 2009;XIV (2): 28-32.
 14. **Trifa AP**, Popp RA, Militaru MS, Crisan TO, Farcas MF, Csernik FA, Petrisor F, Pop IV, Buzoianu AD. The C and T alleles of the MDR1 C3435T polymorphism share similar frequencies in the Romanian population. *Annals of RSCB*. 2009;XIV(1):68-73.
 15. Popp RA, **Trifa AP**, Militaru M, Crisan TO, Petrisor F, Farcas MF, Csernik FA, Pop IV. Methionine synthase reductase (MTRR) gene 66G>A polymorphism as a possible risk factor for recurrent spontaneous abortion. *Annals of RSCB*. 2009;XIV(1):28-33.
 16. Crisan TO, **Trifa AP**, Farcas MF, Csernik FA, Petrisor F, Militaru M, Pop IV, Popp RA. The C936T polymorphism of the VEGF gene in Romanians – distribution analysis in healthy volunteers and in recurrent spontaneous abortion patients. *Annals of RSCB*. 2009;XIV(1);91-97.